Brought to you by 
IPO grosses €97.75mm for Movetis NV
07 Jan 2010
Executive Summary
Belgian biotech Movetis NV (focused on gastrointestinal disorders) has grossed €97.75mm ($147mm) through its initial public offering of 7.9mm shares at €12.25 each (including the overallotment). The shares were originally priced to sell at between €11.25 and €14.25. The company will trade on Euronext Brussels under the ticker MOVE.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
IPO grosses €97.75mm for Movetis NV
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice